American Association for Cancer Research
Browse
00085472can090685-sup-sfig_3.pdf (37.84 kB)

Supplementary Figure 3 from Antigen Presented by Tumors In vivo Determines the Nature of CD8+ T-Cell Cytotoxicity

Download (37.84 kB)
journal contribution
posted on 2023-03-30, 18:40 authored by Anil Shanker, Alan D. Brooks, Kristen M. Jacobsen, John W. Wine, Robert H. Wiltrout, Hideo Yagita, Thomas J. Sayers
Supplementary Figure 3 from Antigen Presented by Tumors In vivo Determines the Nature of CD8+ T-Cell Cytotoxicity

History

ARTICLE ABSTRACT

The biological relevance of the perforin and Fas ligand (FasL) cytolytic pathways of CD8+ T lymphocytes (CTL) for cancer immunotherapy is controversial. We investigated the importance of these pathways in a murine renal cell carcinoma expressing influenza viral hemagglutinin as a defined surrogate antigen (Renca-HA). Following Renca-HA injection, all FasL-dysfunctional FasLgld/gld mice (n = 54) died from Renca-HA tumors by day 62. By contrast, perforin−/− (51%; n = 45) and Faslpr/lpr (55%; n = 51) mice remained tumor-free at day 360. Blocking FasL in vivo inhibited tumor rejection in these mice. Moreover, established Renca-HA tumors were cleared more efficiently by adoptively transferred HA518-526–specific T-cell receptor–transgenic CTL using FasL rather than perforin. Strikingly, a range of mouse tumor cells presenting low concentrations of immunogenic peptide were all preferentially lysed by the FasL but not the Pfp-mediated effector pathway of CTL, whereas at higher peptide concentrations, the preference in effector pathway usage by CTL was lost. Interestingly, a number of human renal cancer lines were also susceptible to FasL-mediated cytotoxicity. Therefore, the FasL cytolytic pathway may be particularly important for eradicating Fas-sensitive tumors presenting low levels of MHC class I–associated antigens following adoptive T-cell therapy. [Cancer Res 2009;69(16):6615–23]